Please login to bookmark Close

Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au